← Back to Screener
Addex Therapeutics Ltd American Depositary Shares (ADXN)
Price$6.81
Favorite Metrics
Price vs S&P 500 (26W)-30.24%
Price vs S&P 500 (4W)25.76%
Market Capitalization$9.29M
P/E Ratio (Annual)1.03x
All Metrics
Book Value / Share (Quarterly)$0.07
P/TBV (Annual)1.09x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-49.34%
Cash Flow / Share (Quarterly)$-0.02
Price vs S&P 500 (YTD)-11.63%
Net Profit Margin (TTM)-1026.72%
EPS (TTM)$-0.07
10-Day Avg Trading Volume0.25M
EPS Excl Extra (TTM)$-0.07
Revenue Growth (5Y)-32.06%
EPS (Annual)$0.09
ROI (Annual)72.60%
Gross Margin (Annual)-958.33%
Net Profit Margin (5Y Avg)-234.68%
Cash / Share (Quarterly)$0.02
Revenue Growth QoQ (YoY)-15.00%
P/E Normalized (Annual)1.03x
ROA (Last FY)66.08%
Revenue Growth TTM (YoY)-6.27%
EBITD / Share (TTM)$-0.03
ROE (5Y Avg)-289.98%
Operating Margin (TTM)-375.41%
Cash Flow / Share (Annual)$-0.07
P/B Ratio1.22x
P/B Ratio (Quarterly)2.01x
Net Income / Employee (Annual)$5
EV / Revenue (TTM)9.23x
Net Interest Coverage (TTM)-1.28x
ROA (TTM)-63.34%
EPS Incl Extra (Annual)$0.09
Current Ratio (Annual)4.42x
Quick Ratio (Quarterly)1.91x
3-Month Avg Trading Volume0.20M
52-Week Price Return-67.43%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.07
P/S Ratio (Annual)17.75x
Asset Turnover (Annual)0.04x
52-Week High$0.09
Operating Margin (5Y Avg)-607.12%
EPS Excl Extra (Annual)$0.09
CapEx CAGR (5Y)-46.31%
Tangible BV CAGR (5Y)-9.79%
26-Week Price Return-26.25%
Quick Ratio (Annual)4.20x
13-Week Price Return-11.35%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.01x
Enterprise Value$6.545
Revenue / Share Growth (5Y)-47.69%
Asset Turnover (TTM)0.06x
Book Value / Share Growth (5Y)-36.58%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-1197.28%
Cash / Share (Annual)$0.04
3-Month Return Std Dev83.91%
Gross Margin (5Y Avg)-178.93%
Net Income / Employee (TTM)$-4
ROE (Last FY)72.91%
Net Interest Coverage (Annual)-0.56x
EPS Basic Excl Extra (Annual)$0.09
Receivables Turnover (TTM)5.25x
Total Debt / Equity (Quarterly)0.01x
EPS Incl Extra (TTM)$-0.07
Receivables Turnover (Annual)20.05x
ROI (TTM)-72.84%
P/S Ratio (TTM)13.11x
Pretax Margin (5Y Avg)-720.46%
Revenue / Share (Annual)$0.01
Tangible BV / Share (Annual)$0.13
Price vs S&P 500 (52W)-66.60%
Year-to-Date Return-9.75%
5-Day Price Return9.65%
EPS Normalized (Annual)$0.09
ROA (5Y Avg)-108.73%
Net Profit Margin (Annual)1720.76%
Month-to-Date Return29.53%
Cash Flow / Share (TTM)$-0.27
EBITD / Share (Annual)$-0.04
Operating Margin (Annual)-671.94%
LT Debt / Equity (Annual)1.77x
ROI (5Y Avg)-240.31%
LT Debt / Equity (Quarterly)0.53x
EPS Basic Excl Extra (TTM)$-0.07
P/TBV (Quarterly)2.01x
P/B Ratio (Annual)1.09x
Pretax Margin (TTM)-1045.06%
Book Value / Share (Annual)$0.13
Price vs S&P 500 (13W)-12.04%
Beta0.26x
P/FCF (Annual)4.18x
Revenue / Share (TTM)$0.01
ROE (TTM)-73.21%
52-Week Low$0.03
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ADXNAddex Therapeutics Ltd American Depositary Shares | 13.11x | -6.27% | — | — | $6.81 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company specializing in the development of allosteric modulators, an emerging class of orally available small-molecule drugs. Operating from its base in Switzerland and Europe, the company focuses on the discovery, development, and commercialization of these novel therapeutics.